tbuckley/cabot-search huggingface dataset:
LBA6 A phase II, single arm, open label, Simon two-stage study of pembrolizumab in metastatic HER2-negative breast cancer patients: Evaluation of impact of germline variants in APOBEC3B (AUROR)
Authors: G.F. Ho, S.C. Lee, J.W. Pan, A.Z. Bustam, A. Alip, N.F. Bt Abdul Satar, M. Saad, R. Abdul Malik, S.E. Lim, S. Ow, N.Y.L. Ngoi, K.B. Law, Y.Y. Toh, B. Selvam, J. Lim, S-H. Teo
Journal: Annals of Oncology (2023)
LBA7 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the KEYNOTE-177 study Asia subgroup
Authors: T. Yoshino, T. André, T.W. Kim, W.P. Yong, K-K. Shiu, B. Vittrup Jensen, L.H. Jensen, C.J.A. Punt, D. Smith, R. Garcia-Carbonero, J. Alcaide-Garcia, P. Gibbs, C. de la Fouchardiere, F. Rivera, M.E. Elez Fernandez, D.T. Le, Y. Zuo, D. Fogelman, D.E. Adelberg, L. Diaz
Journal: Annals of Oncology (2023)
125P Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Authors: A. Tryakin, M. Fedyanin, M. Mariam, F.V. Moiseenko, O. Mironov, D. Stroyakovskiy, R.V. Orlova, N. Sokolov, S. Orlova, E. Mantsyrev, A.V. Sultanbaev, A. Teterich, K. Babina, D. Iukalchuk, S. Borzyanitsa, A. Isiangulova, A. Saydullaeva, I. Chernova, E. Bobrova, N. Fadeeva
Journal: Annals of Oncology (2023)
40P Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Authors: J.W. Pan, H. Makmur, P-S. Ng, J-Y. Tai, S.N. Hasan, C.H. Yip, P. Rajadurai, J. Lim, S-H. Teo
Journal: Annals of Oncology (2023)
139MO Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
Authors: R-H. Xu, D-Y. Oh, K. Kato, H-T. Arkenau, J. Tabernero, M. Cruz-Correa, A.V. Zimina, Y. Bai, J. Shi, K-W. Lee, H. Hirano, D.R. Spigel, L.S. Wyrwicz, R.A. Pazo Cid, L. Li, Y. Xu, M.B. McHenry, S. Yang, M. Moehler
Journal: Annals of Oncology (2023)
59P Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Authors: S.M. Lingaraju, K. Raghavendrachar, G. Balaram, R. Kodandapani, V. Erappareddy, V. Keriyappa, S.N. Ghorpade, S. Patil, S. Chiradoni Thungappa, S. Papaiah Susheela, S. Belagutti Jayappa, S. Bhattacharjee, M. Naseer R, R. Dasgupta, D. Hattangdi, T. Nanjaiah, A. Ravichandran, U. Bahadur, B.S. Ajaikumar, M. Ghosh
Journal: Annals of Oncology (2023)
74MO Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
Authors: D-Y. Oh, F. Meric-Bernstam, V. Makker, A. Oaknin, S. Banerjee, A. Gonzalez Martin, K.H. Jung, I. Lugowska, L.M. Manso, A. Manzano, B. Melichar, S. Siena, D. Stroyakovskiy, A. Fielding, Y. Ma, S.D. Puvvada, J-Y. Lee
Journal: Annals of Oncology (2023)
607P Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan
Authors: N. Yamazaki, S. Wada, D. Ogata, E. Nakano, T. Kashihara, K. Okuma, H. Eto, A. Takahashi, H. Igaki, K. Namikawa
Journal: Annals of Oncology (2023)
614P The role of PD-L1 expression in prognosis of osteosarcoma patients: A systematic review and meta-analysis
Authors: A.E. Purnomo, M. Geraldi Lokanata, G.H. Tumiwa, B.L. Frandi, J.H. Wijaya, E.F. Lokanata, R.S. Heriyanto, A. Kurniawan
Journal: Annals of Oncology (2023)
611P ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)
Authors: P. Mando, M.S. Faisal, K. Jatwani, S. Seghers, J. Young, L-A.M.N. Teuwen, H. Prenen, T.T.V. Luong, E. Segelov
Journal: Annals of Oncology (2023)
129O Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
Authors: D-Y. Oh, Y.Y. Janjigian, S-E. Al-Batran, Z.A. Wainberg, E. van Cutsem, D. Molena, K. Muro, W.J. Hyung, L.S. Wyrwicz, T. Omori, M. Moehler, M. Garrido, S. Cunha Sousa Oliveira, M. Liberman, V. Castro Oliden, M. Bilici, J. Kurland, I. Xynos, H. Mann, J. Tabernero
Journal: Annals of Oncology (2023)
142P The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Authors: M. Rimini, M. Persano, S. Foti, L. Fornaro, S. Lonardi, M. Niger, E. Tamburini, D. Lavacchi, I.G. Rapposelli, E. Martinelli, I. Garajova, F. Simionato, S. Camera, F. Rossari, E. Amadeo, F. Vitiello, S. Cascinu, L. Rimassa, L. Antonuzzo, A. Casadei Gardini
Journal: Annals of Oncology (2023)
83P The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Authors: Y. Shen, S. Rahimian, A. Qin, None Y. Qiu, T. Fang, X. Liang, Y. Li, Q. Tan, R. Zhao, X. Bai, T. Liang
Journal: Annals of Oncology (2023)
20P Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Authors: Y. Ji, J. Wang, G. Dai, F. Zhou, Q. Meng, Q. Wu, H. Qu, H. Liu, M. Liu, Y. Tian, X. Tan, W. He, Z. Qin, H. Tang, G. Luo, Y. Liu, Y. Ren, J. Luo, M. Wang, P. Lu
Journal: Annals of Oncology (2023)
1MO Image biomarker discovery from DCE-MRI for identifying responders of MK-2206 on early-stage breast cancer patients: A secondary radio-genomics analysis of I-SPY2 trial
Authors: J. Zhang, X. Teng, Q. Lai, X. Zhang, X. Fan, T. Zhou, Y-H. Huang, C. Jing
Journal: Annals of Oncology (2023)
78P First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Authors: C.J. Yen, M-C. Liu, J. Fan, C. Sun, P. Peng, X. Du, J. Wang, F. Wei, Z. Gou, X. Tan, D. Wu, F. Wu, C-L. Ho
Journal: Annals of Oncology (2023)
57MO First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in HR+/HER2− advanced breast cancer (ABC): A post hoc analysis of Asian and non-Asian patients (pts) from the phase II RIGHT choice trial
Authors: Y-S. Yap, S-A. Im, Y-S. Lu, H.A. Azim, Y. Eralp, G.B. Kanakasetty, H. Abdel-Razeq, L. Zhukova, A. Thuerigen, T. Delgar Alfaro, J. Wu, M. Gao, N.S. El Saghir
Journal: Annals of Oncology (2023)
602P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
Authors: A.M. Haydon, D. Schadendorf, R. Dummer, K.T. Flaherty, C. Robert, A.M. Arance Fernandez, J.W. de Groot, C. Garbe, H. Gogas, R. Gutzmer, I. Krajsova, G. Liszkay, C. Loquai, M. Mandalà, N. Yamazaki, C.A. Guenzel, A. Polli, M. Thakur, A. Di Pietro, P.A. Ascierto
Journal: Annals of Oncology (2023)
73TiP Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Authors: H. Iwata, E.P. Hamilton, C.X. Ma, M. De Laurentiis, S.A. Hurvitz, S.A. Wander, M.A. Danso, D.R. Lu, J. Perkins, Y. Liu, L. Tran, S. Anderson, C. Chappey, D.Z. Yang, M. Campone
Journal: Annals of Oncology (2023)
618P Adult renal Ewing’s sarcoma/primitive neuroectodermal tumor: A 20-year retrospective review of molecular histopathological profiles, and clinical outcomes
Authors: J.T. Georgy, Z. Thomas, D.B. Thumaty, A. Joel, V.R. Gopinathan, R. Pai, A.O. John, S. Devabhaktuni, J.P. Wisely, N.T. John, R. Balakrishnan, A. Augustine, A. Chandramohan, J. Rani, R.T. Chacko, A. Singh
Journal: Annals of Oncology (2023)
50P A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Authors: A. Kardousha, W. Shehada, A. Basha, S. Nasser, M.M. El Mistiri, A. Hamad, S.B. Bujassoum, S. Elazzazy
Journal: Annals of Oncology (2023)
107P Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Authors: S. Suresh, K. Sekar, V. R, K. Kallur, S. Swamy, S. Ct, S. Bj, S. Patil, A. Bs, G. Lohith
Journal: Annals of Oncology (2023)
117P Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Authors: V. Wong, J. McKenzie, S. Kosmider, R. Wong, Y.H. To, J. Shapiro, C. Dunn, M. Burge, W. Hong, S. Caird, S.H-S. Lim, H-L. Wong, B. Lee, B.B.Y. Ma, P. Gibbs
Journal: Annals of Oncology (2023)
32P Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Authors: M. Tada, Y. Kikawa, C. Hirai, H. Yanai, N. Shibata, T. Sugie
Journal: Annals of Oncology (2023)
141P Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Authors: A. Cammarota, I. Turgeman, F. Aghayeva, R. Woodford, R.M. Grochot, J. Choy, A. De Burgh Williams, H-T. Arkenau, E. Fontana
Journal: Annals of Oncology (2023)
147P Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Authors: S.L. Chan, B. Sangro, R.K. Kelley, G. Lau, M. Kudo, W. Sukeepaisarnjaroen, E.N. De Toni, J. Furuse, Y-K. Kang, P.R. Galle, L. Rimassa, A. Heurgue, V.C. Tam, T.V. Dao, S. Chiradoni Thungappa, V. Breder, Y.V. Ostapenko, M.E. Reig Monzon, C. Gupta, G.K. Abou-Alfa
Journal: Annals of Oncology (2023)
604P Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status
Authors: M.S. Brose, B. Keam, B. Robinson, S. Sherman, J.A. Krajewska, C-C. Lin, F. Vaisman, A.O. Hoff, E. Hitre, D.W. Bowles, N. Ngamphaiboon, X. Guo, F. Zhang, M. Schwickart, D.S. Williamson, D. Curran, N. Berry, J. Capdevila Castillon
Journal: Annals of Oncology (2023)
101P The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Authors: K. Ouchi, S. Wakayama, S. Takahashi, Y. Yamada, Y. Komatsu, K. Shimada, T. Yamaguchi, H. Shirota, M. Takahashi, C. Ishioka
Journal: Annals of Oncology (2023)
34P Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Authors: N. Sinarajoo, Y.C. Kong, R. Kaur, B.L. Sew, M. Thiagarajan, N.F. Bt Abdul Satar, A. Ali, F.L.T. Chong, N.H. Zainal, A.F. Abdul Aziz, S. Jaya-Prakason, H.D. Alagir Rajah, N. Muniandy, M. Danaee, C.H. Yip, N. Bhoo-Pathy
Journal: Annals of Oncology (2023)
81P A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Authors: Q. Liu, B. Liu, J. Wei, R. Li, J. Shao, L. Zhu, M. Tian, L. Yu
Journal: Annals of Oncology (2023)
80P Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Authors: Y. Wu, H. Jing, J. Zhang, X. Cao, K. Li, Y. Liu, M. Meng, H. Li, W. Kang, J. Li, Q. Wang, J. Zhu
Journal: Annals of Oncology (2023)
97P Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Authors: R-H. Xu, Z. Chen, H-W. Teng, H. Pan, H. Zhong, A. Takashima, T-S. Yang, Y-M. Yeh, Y. Deng, T.W. Kim, T-Y. Kim, J.O. Park, M.A. Lee, S. Lee, K-H. Yeh, T. Yoshino, R. Fu, R. Jain, D.E. Adelberg, A. Kawazoe
Journal: Annals of Oncology (2023)
152P Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Authors: F. Koga, T. Shirakawa, M. Shimokawa, T. Otsuka, H. Shimokawa, J. Nakazawa, H. Oda, S. Takeshita, Y. Kawaguchi, S. Arita, H. Taguchi, T. Sakai, K. Nishikawa, S. Arima, Y. Ueda, M. Kawahira, T. Sakae, Y. Ide, T. Mizuta, K. Mitsugi
Journal: Annals of Oncology (2023)
56MO Landscape of ESR1 mutations in advanced breast cancer using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and Middle East (AME)
Authors: S. Dawood, M. Al Akasheh, T. Peretz-Yablonski, N.E. Ben-Baruch, N. Sandhir, S.S. Jain
Journal: Annals of Oncology (2023)
95P Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Authors: S.K. Barik, P. Mukherjee, S.K.K. Das Majumdar, D.K. Das, D.K. Muduly, B. Pattnaik, T. Dutta, S. Gupta, M.R. Sahoo, P.K. Sasmal, S. Patra, B. Sahoo, H.K. Nayak, A.K. Singh, D.K. Parida
Journal: Annals of Oncology (2023)
161P Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Authors: T. Fujii, G. Prager, S. Boeck, D. Santini, D.P. Modest, F. Rivera, J.M. Phelip, M.H. Dioca, E. Smyth, A. Zaanan, H.S. Wasan, J. Furuse
Journal: Annals of Oncology (2023)
127P A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Authors: T. Yoshino, N. Hooda, D. Younan, K. Muro, K. Shitara, V. Heinemann, B. O’Neil, F. Rivera Herrero, M. Peeters, J. Soeda, M. Suh, H. Reichart, K. Mezzi, J. Fryzek, V. Chia, M. Rehn, S. Stintzing
Journal: Annals of Oncology (2023)
140P Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Authors: Y-J. Bang, L. Shen, Y-K. Kang, Y. Chao, H.H.F. Soo, P. Sunpaweravong, D. Moran, A. Guerrero, R. Li, J. Pavese, M. Matsangou, P. Bhattacharya, K. Shitara, R-H. Xu
Journal: Annals of Oncology (2023)
174P Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Authors: B. Lee, J. Yousef, K.Y. Fung, S. Emery-Corbin, L. Dagley, P. Baldoni, G. Smyth, P. Gibbs, T. Putoczki
Journal: Annals of Oncology (2023)
168P Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Authors: Z. Lu, M. Geng, Y. Han, J. Cao, J. Wang, T. Liu, X. Yuan, X. Meng, Y. Zhang, R. Zhao, L. Wan, E. Li, W. Wang, Z. Li, D.F. Shi, Q. Jing, S. Shi, F. Dong, L. Shen
Journal: Annals of Oncology (2023)
96P Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Authors: J. Zhang, Q. Dong, Y. Wang, Y. Diao, X. Cui, L. Man, J. Zhang, Y. Zhang, T. Wu, T. Chen, Y. Dong, J. Zhang, Y. Huang, S. Wang
Journal: Annals of Oncology (2023)
116P Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Authors: M.H. Chhayani, M. Khealani, S.K. Yadav, S.J. Obulareddy, H.D. Chhayani, H.D. Desai, T. Patel, R. Patel
Journal: Annals of Oncology (2023)
46P Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Authors: T. Mistry, R. Pal, S. Ghosh, P. Nath, N. Alam, V.D. Nasare
Journal: Annals of Oncology (2023)
610P Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation
Authors: S. Seghers, P. Mando, C.J.L. Tan, M. Eid, A.S. Jayraj, L-A.M.N. Teuwen, J. Young, E. Segelov, H. Prenen
Journal: Annals of Oncology (2023)
LBA3 Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysis
Authors: Y.H. Park, S-A. Im, J-H. Ahn, M.H. Kim, J. Cortés, R.A. Dent, L. Pusztai, H.L. McArthur, S. Kummel, C. Denkert, J. O'Shaughnessy, M-A. Mouret-Reynier, M.I.R. Ferreira, M. Gion Cortes, J-F. Boileau, R. Hui, Y. Zhu, W. Pan, V.V. Karantza, P. Schmid
Journal: Annals of Oncology (2023)
LBA4 Sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in Asian patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (mBC): Results from the phase III EVER-002 study
Authors: B. Xu, F. Ma, S. Wang, M. Yan, W. Li, J. Sohn, J. Tang, X. Wang, Y. Wang, S-A. Im, D. Jiang, T. Valdez, Y. Zhang, K.M. Komatsubara, W-P. Chung
Journal: Annals of Oncology (2023)
155P Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Authors: J. Du, F. Tong, H. Sha, Y. Sun, Y. Zhu, L. Qi, X. Li, W. Li, Y. Yang, Z. Li, C. Xu, J. Ni, X. Zhang, C. Zhu, X. Wang, X. Qian, B. Liu
Journal: Annals of Oncology (2023)
18P Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Authors: A.K. Vaid, O. Pagani, A.C. Ramesh, A. Bharthuar, C.J. Desai, G. Biswas, J. Wadhwa, P.N. Mohapatra, S. Gulia, P.V.S.S. Sripada, T.P. Sahoo, V. Agarwal, F. Dawer, R.R. Desai, K. Gaurav, B.P. Kotak
Journal: Annals of Oncology (2023)
169P Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Authors: K. Wang, H. Sun, X. Bai, Z-Y. Huang, T. Song, M. Chen, M. Kuang, B. Xiang, Y. Zeng, L-X. Liu, D. Li, Y. Chen, J. Cai, B. Xing, T. Peng, X. Zhang, X. Zhu, J. Zhou, J. Fan, F. Shen
Journal: Annals of Oncology (2023)
115P Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Authors: M-C. Hsieh, H-P. Chen, K-M. Rau, S-E. Lin, K-W. Liu, C-C. Chiu, C-I. Chen, L-C. Song
Journal: Annals of Oncology (2023)
128TiP A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Authors: R. Lin, S. Zhao, L. Su, Y. Hong, J. Luo, Y. Wei, S. Zhao
Journal: Annals of Oncology (2023)
75MO Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3+ tumors: Focus on Asian pts
Authors: Y. Kuboki, V. Gambardella, J. Capdevila Castillon, O.B. Alese, D. Morgensztern, C.M. Sayehli, M.F. Sanmamed, E. Arriola, J. Wolf, T.K. Owonikoko, M. Studeny, M. Bouzaggou, E. Song, M. Wermke
Journal: Annals of Oncology (2023)
123P Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Authors: D.S. Hoon, S. Furuhashi, S. Mizuno, S. Ryu, Y.B. Naeini, A.J. Bilchik, M.A. Bustos
Journal: Annals of Oncology (2023)
16P Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Authors: J-I. Lai, Y. Antill, K.H. Jung, C. Shimizu, M.L. Abesamis Tiambeng, L-M. Tseng, E.M. Tan, S. Qu, C. Spiteri, S.Y. Ihm, D. Hsu
Journal: Annals of Oncology (2023)
120P Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Authors: X. Yang, G. Guo, H. Zhou, Z. Liu, R. Li, H. Shen, X. Yin, Y. Zeng, W. Liu, F. Xiang, S. Jiang, X. Qu
Journal: Annals of Oncology (2023)
154P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Authors: M. Persano, M. Rimini, T. Tada, G. Suda, S. Shimose, M. Kudo, C. Yoo, J. Cheon, F. Finkelmeier, H.Y. Lim, J. Presa, G. Masi, F. Bergamo, M.A. Iavarone, G. Cabibbo, F.G. Foschi, F. Piscaglia, S. Cascinu, M. Scartozzi, A. Casadei Gardini
Journal: Annals of Oncology (2023)
133MO Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966
Authors: R.S. Finn, M. Ueno, C. Yoo, Z. Ren, J. Furuse, R.K. Kelley, S.L. Chan, J. Edeline, H.J. Klumpen, T. Yau, S.C. Oh, M. Ozaka, J.G. Kim, J.O. Park, A. Vogel, J.W. Valle, L. Yu, U. Malhotra, A.B. Siegel, S. Qin
Journal: Annals of Oncology (2023)
86P Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Authors: C. Li, D. Zhu, Z. Fan, Y. Chen, Y. Chen, Y. Li, M. Ji, P. Duan, J. Su, J. Yang, Y. Tang, M. Zhang, S. Wang, G. Yu, Y. Huang, R. Chen, X. Hu, L. Wang, Q. Wang, J. Zhu
Journal: Annals of Oncology (2023)
92MO Sotorasib (Soto) + panitumumab (Pmab) and FOLFIRI in previously treated KRASG12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy for CodeBreaK 101 phase Ib expansion cohort
Authors: T. Masuishi, J.H. Strickler, J-P. Machiels, D.S. Hong, R. Greil, E. Chan, J. Hippenmeyer, Y. Saportas, P. Cardona, C. Xia, Y. Kuboki
Journal: Annals of Oncology (2023)
151P Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Authors: E. Kuroki, K. Nio, M. Shimokawa, T. Otsuka, J. Nakazawa, T. Shibuki, S. Arima, K. Miwa, F. Koga, Y. Ueda, Y. Kubotsu, H. Shimokawa, S. Takeshita, K. Nishikawa, A. Hosokawa, H. Oda, S. Arita, T. Shirakawa, T. Mizuta, K. Mitsugi
Journal: Annals of Oncology (2023)
55O Phase I study of H3B-6545 in patients (pts) with estrogen receptor-positive (ER+) breast cancer
Authors: M. Ono, T. Kogawa, S. Kitano, T. Shimoi, K. Yamamoto, S. Kobayashi, Y. Ichikawa, K. Yamaguchi, Y. Otake, S. Hojo, K. Yonemori
Journal: Annals of Oncology (2023)
173P Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Authors: M. Persano, M. Rimini, T. Tada, G. Suda, S. Shimose, M. Kudo, C. Yoo, J. Cheon, F. Finkelmeier, H.Y. Lim, J. Presa, G. Masi, F. Bergamo, M.A. Iavarone, G. Cabibbo, F.G. Foschi, F. Piscaglia, S. Cascinu, M. Scartozzi, A. Casadei Gardini
Journal: Annals of Oncology (2023)
177P Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Authors: P.T. Vaghela, H.A.R. Bashir, S.K. Yadav, S.J. Obulareddy, M. Khealani, R. Patel, S. Gangireddy, H. Thogata
Journal: Annals of Oncology (2023)
616P Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Authors: P.G. Franco, G.R.M. Alcala, R.D.B. Maravilla, A.M.M. Pascual-Panganiban, J.C. Pilapil, A.E. Gorospe
Journal: Annals of Oncology (2023)
145P Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Authors: L. Chen, Y. Liao, T. Jiang, M. Kang, X. Mei, L. Tan, J. Liu, Z. Zhang, W. Yu, L. Li, H. Jiang
Journal: Annals of Oncology (2023)